Vertex Pharmaceuticals Incorporated vs Wheaton Precious Metals Corp — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B), while Wheaton Precious Metals Corp trades at $103.33 (market cap $46.54B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.6× Wheaton Precious Metals Corp's market cap, and Wheaton Precious Metals Corp pays a 0.75% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WPM | |
|---|---|---|
Market Cap | $121.95B | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $529.59 | $165.72 |
52-Week Low | $366.54 | $91.00 |
Enterprise Value | $116.69B | $44.39B |
Dividend Yield | — | 0.75% |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →